Specialty Pharmacy

The analysis evaluated emerging mutations in patients with relapsed/refractory acute myeloid leukemia receiving gilteritinib therapy in the phase 3 ADMIRAL study.

A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease.

Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.

The financial consequences of becoming disabled can be devastating if pharmacists lack proper financial planning.

Top articles of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

A new method of targeted radiation therapy sends alpha-emitting particles directly to stroma cells in pancreatic cancer tissue.

Top news of the day from across the health care landscape.

Men with breast cancer had higher mortality than women regardless of cancer type, treatment, and access to care.

Top news of the day from across the health care landscape.

Approval was based on results from the phase 3 Impower130 study, which showed atezolizumab in combination with chemotherapy increased overall survival in participants compared with chemotherapy alone.

Top news of the day from across the health care landscape.

Officials from the FDA have approved methotrexate (RediTrex, Cumberland Pharmaceuticals) as an injection for the treatment of adult and pediatric patients with rheumatoid arthritis.

Researchers showed that treating multiple myeloma cells with gamma-secretase inhibitors allowed CAR T-cells to more accurately treat cancer tumors.

It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how Specialty Pharmacists can drive the data standardization conversation during the NASP Annual Meeting in Washington, DC.

The application is based on results from the phase II KEYNOTE-057 trial, which found that pembrolizumab has encouraging activity in patients with high-risk, BCG-unresponsive CIS with or without papillary tumors.

Trastuzumab-dkst (Ogivri, Mylan, Biocon), a biosimilar to trastuzumab (Herceptin, Genentech Inc.), has been launched in the US, according to an announcement from Mylan N.V. and Biocon Ltd. It is the first biosimilar approved by the FDA and recommended by the FDA Oncologic Drugs Advisory Committee.

Top news of the day from across the health care landscape.

Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss during the future of data in Specialty Pharmacy at the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss value-based care and whether or not it poses challenge to data standardization in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

The findings suggest that biologics can be used for those with elderly-onset rheumatoid arthritis (RA) as effectively as for those with young-onset RA.

Top news of the day from across the health care landscape.

The phase 3b/4 SPIRIT head-to-head study evaluated ixekizumab (Taltz) versus adalimumab (Humira) in psoriatic arthritis.

The FDA approved elexacaftor/tezacaftor/ivacaftor (Trikafta) earlier this month based on the results of a phase 3 clinical trial.

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.